Literature DB >> 15907950

Neuroprotective effects of novel small peptides in vitro and after brain injury.

Alan I Faden1, Vilen A Movsesyan, Susan M Knoblach, Farid Ahmed, Ibolja Cernak.   

Abstract

Thyrotropin-releasing hormone (TRH) and TRH analogues have been reported to be neuroprotective in experimental models of spinal cord injury and head injury. We have previously shown that a diketopiperazine structurally related to the TRH metabolite cyclo-his-pro reduces neuronal cell death in vitro and in vivo. Here we report the neuroprotective activity of other cyclic dipeptides in multiple in vitro models of neuronal injury and after controlled cortical impact (CCI) in mice. Using primary neuronal cultures, three novel dipeptides were compared to the previously reported diketopiperazine as well as to vehicle controls; each of the compounds reduced cell death after direct physical trauma or trophic withdrawal. Two of these peptides also protected against glutamate toxicity and beta-amyloid-induced injury; the latter also strongly inhibited glutamate-induced increases in intracellular calcium. Treatment with each of the test compounds resulted in highly significant improvement of motor and cognitive recovery after CCI, as well as markedly reducing lesion volumes as shown by high field magnetic resonance imaging. DNA microarray studies following fluid percussion induced traumatic brain injury (TBI) in rats showed that treatment with one of these dipeptides after injury significantly down-regulated expression of mRNAs for cell cycle proteins, aquaporins, cathepsins and calpain in ipsilateral cortex and/or hippocampus, while up-regulating expression of brain-derived neurotrophic factor, hypoxia-inducible factor and several heat-shock proteins. Many of these mRNA expression changes were paralleled at the protein level. The fact that these small peptides modulate multiple mechanisms favoring neuronal cell survival, as well as their ability to improve functional outcome and reduce posttraumatic lesion size, suggests that they may have potential utility in clinical head injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907950     DOI: 10.1016/j.neuropharm.2005.04.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  23 in total

Review 1.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

Review 2.  Role of cell cycle proteins in CNS injury.

Authors:  Kimberly R Byrnes; Alan I Faden
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

Review 3.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 4.  Cell cycle activation and spinal cord injury.

Authors:  Junfang Wu; Bogdan A Stoica; Alan I Faden
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

5.  Alpha II Spectrin breakdown products in immature Sprague Dawley rat hippocampus and cortex after traumatic brain injury.

Authors:  Michelle E Schober; Daniela F Requena; Lizeth J Davis; Ryan R Metzger; Kimberly S Bennett; Denise Morita; Christian Niedzwecki; Zhihui Yang; Kevin K W Wang
Journal:  Brain Res       Date:  2014-06-12       Impact factor: 3.252

Review 6.  Neuroprotection for traumatic brain injury.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Handb Clin Neurol       Date:  2015

7.  Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury.

Authors:  David L Brody; Christine Mac Donald; Chad C Kessens; Carla Yuede; Maia Parsadanian; Mike Spinner; Eddie Kim; Katherine E Schwetye; David M Holtzman; Philip V Bayly
Journal:  J Neurotrauma       Date:  2007-04       Impact factor: 5.269

8.  The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.

Authors:  Caitlin M Daimon; Patrick Chirdon; Stuart Maudsley; Bronwen Martin
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

Review 9.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

Review 10.  IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.

Authors:  Jian Guan; Peter D Gluckman
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.